ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021
[Expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma].
Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Chinese expert consensus on the clinical application of molecular diagnostics in hepatobiliary cancers (2024 edition).Liver research (Beijing, China) · 2024Article
- Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.Journal of clinical laboratory analysis · 2023Article
- Application of the Multi-Omics Liquid Biopsy Method M2P-HCC in Early Liver Cancer Screening for High-Risk Individuals with Hepatitis B-Related Liver Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- MUTYH is a potential prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma.Liver research (Beijing, China) · 2022Article
- Screening of Hepatocellular Carcinoma in Hepatic Cirrhosis Patients by a Novel Blood-Based Multi-Omics Test.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The disease burden of hepatocellular carcinoma in our country is serious, and the prognosis is not ideal. Therefore, early screening of high-risk groups of hepatocellular carcinoma through simple methods is the key to achieving early diagnosis and treatment and improving survival. At present, alpha fetoprotein (AFP) and other hematological tests are still the main methods in the early screening of hepatocellular carcinoma, but their sensitivity and specificity are limited, and the risk of missed diagnosis is high. In recent years, with the continuous development of science and technology, the improvement of traditional detection methods and the emergence of new markers such as methylated DNA and miRNA have brought hope for further improving the sensitivity and specificity of early hepatocellular carcinoma screening. This consensus summarizes the research progress of traditional and new hematological examination methods, and puts forward the expert guidance on the role of hematological markers in the early screening of hepatocellular carcinoma; with aim to provide a basis for improving the prevention and control level in China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.